Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

about

Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.

P2860

Q36542670-E1948A10-8962-4E4D-A1A9-E24F7890E310 Q51622395-1633194D-647B-4BB3-86D5-96E5FF18FF04

P2860

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

Item

http://www.wikidata.org/entity/Q37755220

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

@en

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

@nl

type

Item

label

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

@en

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

@nl

prefLabel

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

@en

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

@nl

P1476

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

@en

P2093

A Morgner-Miehlke

http://www.w3.org/2001/XMLSchema#string

J Labenz

http://www.w3.org/2001/XMLSchema#string

Ku Petersen

http://www.w3.org/2001/XMLSchema#string

S Miehlke

http://www.w3.org/2001/XMLSchema#string

P2860

Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification

Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy

Prevalence of gastro-oesophageal reflux disease in general practice

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease.

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis.

P304

511-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/1744666X.1.4.511

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20477595

http://www.w3.org/2001/XMLSchema#string

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

about

P2860

P2860

Esomeprazole: potent acid suppression in the treatment of acid-related disorders.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698